SEOUL, South Korea,
Aug. 1, 2021 /PRNewswire/ -- LISCure
Biosciences, Inc. ("LISCure") has entered into a know-how license
and development collaboration agreement, and stock purchase
agreement with Mayo Clinic to advance LISCure's microbiome
therapeutics in non-alcoholic steatohepatitis (NASH).
The two entities previously entered a research collaboration
agreement in the first half of 2021 for NASH candidates.
Under the agreement, the company will receive Mayo Clinic's
know-how to establish a new drug development of NASH program. As
part of the agreement, Mayo Clinic will become a shareholder in
LISCure, the first Korean biotech company receiving equity
investment from Mayo Clinic.
The two entities will pursue the common goal of maximizing the
value of LISCure's therapeutics in metabolic diseases by expanding
research and development activities such as discovering new
indications and additional value-added candidates. LISCure plans to
minimize trial and error in preparation for phase 2 clinical trial
of its NASH candidate in the US in 2022 by jointly cooperating with
Mayo Clinic.
"This collaboration will provide innovative treatment
opportunities to patients with high medical needs in various
metabolic diseases. We are very excited to establish a
collaboration with Mayo Clinic," said a company official. "We are
also proud of Mayo Clinic becoming our shareholder and look forward
to continuing a long-term collaboration."
LISCure plans to enter the global clinical trial for NASH
candidate as well as auto-immune disease candidate in the second
half of this year, and to initiate clinical trial in the US for the
world's first novel microbe-mediated cancer therapeutics in the
first half of 2022.
About LISCure Biosciences
LISCure was established in 2018 for the purpose of research and
development of single microbial-based immunotherapy. The main
focused areas are immuno-oncology, neurological diseases,
autoimmune diseases, and metabolic diseases. It develops new drugs
to treat patients as either monotherapy or combination therapy for
major indications.
View original
content:https://www.prnewswire.com/news-releases/liscure-biosciences-announces-know-how-license-agreement-and-stock-purchase-agreement-with-mayo-clinic-301345813.html
SOURCE LISCure Biosciences Inc.